LX211 gets fast tracked

Article

The FDA has granted fast track designation to LX211, a next generation calcineurin inhibitor developed by Lux Biosciences.

The FDA has granted fast track designation to LX211, a next generation calcineurin inhibitor developed by Lux Biosciences.

LX211 is intended for the treatment of non-infectious posterior, intermediate and panuveitis. The fast track designation means that various new means to expedite the development of the drug can now be explored. For example, the company will be allowed to submit portions of the New Drug Application (NDA) for early review as part of a "rolling" submission.

Lux is currently conducting three controlled, double-masked studies aimed at supporting the approval of LX211 as a treatment for uveitis, collectively called the LUMINATE programme. Enrolment is expected to be completed by early 2008 and, if successful, Lux hopes to seek approval later that year.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.